<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640574</url>
  </required_header>
  <id_info>
    <org_study_id>SMRU1102</org_study_id>
    <nct_id>NCT01640574</nct_id>
  </id_info>
  <brief_title>Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)</brief_title>
  <official_title>Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Southeast Asia, Plasmodium vivax (Pv) infection reaches 50-80% and bears a greater burden&#xD;
      of disease than Plasmodium falciparum (Pf). As control over Pf improves, Pv will assume&#xD;
      increasingly larger percentages of malaria prevalence. The chronicity of Pv, due to the&#xD;
      latent liver stage (hypnozoite) not eradicated by chloroquine, causes recurring disability&#xD;
      and compounds the economic burden of those with symptomatic disease. The only widely&#xD;
      available treatment for hypnozoites is primaquine, which, because of challenges with&#xD;
      tolerability, safety in G6PD deficient persons, and compliance, is not commonly prescribed&#xD;
      for the treatment of Pv. Currently, chloroquine is used for the treatment of the blood stages&#xD;
      of Pv, however, there are concerns about increasing parasite resistance. Alternative&#xD;
      treatments, such as artesunate, should be considered in the future of the treatment of blood&#xD;
      stage Pv. The use of primaquine in the treatment of hypnozoites (radical cure) should be&#xD;
      emphasized so that transmission of Pv can be controlled.&#xD;
&#xD;
      This study aims to determine the optimal primaquine regimen for radical cure of Plasmodium&#xD;
      vivax. Chloroquine is currently the standard of treatment for Plasmodium vivax. Chloroquine&#xD;
      may have synergistic effects when used with primaquine and due to its long half-life may&#xD;
      delay the first relapse of vivax malaria. In contrast, artesunate does not have documented&#xD;
      interactions with primaquine and has a very short half-life, thus, presumably will have no&#xD;
      impact on first relapse. Combining primaquine with these two anti-malarials may lead to an&#xD;
      alternative regimen for Pv infection and changing the primaquine dosing regimen may lead to a&#xD;
      more practical and efficacious therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of P. vivax</measure>
    <time_frame>52 weeks</time_frame>
    <description>Recurrence with Plasmodium vivax malaria within 52 weeks of first treatment dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Number of adverse events within 28 days of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of P. vivax</measure>
    <time_frame>6 months</time_frame>
    <description>Recurrence with Plasmodium vivax malaria within 6 months of first treatment dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug concentrations</measure>
    <time_frame>63 days</time_frame>
    <description>Chloroquine, piperaquine and primaquine drug levels</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">680</enrollment>
  <condition>Vivax Malaria</condition>
  <arm_group>
    <arm_group_label>DHA-P 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA-P 14 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine 7 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine 14 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-Piperaquine</intervention_name>
    <description>Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days</description>
    <arm_group_label>DHA-P 7 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-Piperaquine</intervention_name>
    <description>Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days</description>
    <arm_group_label>DHA-P 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days</description>
    <arm_group_label>Chloroquine 7 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days</description>
    <arm_group_label>Chloroquine 14 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 6 months old&#xD;
&#xD;
          -  Microscopic diagnosis of Plasmodium vivax malaria mono-infection&#xD;
&#xD;
          -  Participant or parent/guardian is willing and able to give informed consent for&#xD;
             participation in the study&#xD;
&#xD;
          -  Able (in the Investigators opinion) and willing to comply with all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe malaria&#xD;
&#xD;
          -  History of allergy or adverse reaction to artesunate, piperaquine, chloroquine, or&#xD;
             primaquine&#xD;
&#xD;
          -  Blood transfusion in the past 3 months&#xD;
&#xD;
          -  G6PD deficiency by rapid test&#xD;
&#xD;
          -  Hematocrit ≤ 25%&#xD;
&#xD;
          -  Pregnancy at the time of screening&#xD;
&#xD;
          -  Breastfeeding an infant &lt; 6 months old&#xD;
&#xD;
          -  Presence of any condition which in the judgement of the investigator would place the&#xD;
             subject at undue risk or interfere with the results of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Nosten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cindy Chu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shoklo Malaria Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shoklo Malaria Research Unit</name>
      <address>
        <city>Mae Sot</city>
        <state>Tak</state>
        <zip>63110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vivax</keyword>
  <keyword>Chloroquine</keyword>
  <keyword>Primaquine</keyword>
  <keyword>Dihydroartemisinin-Piperaquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Artenimol</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

